title: [Amifostin in protection of kidney from cisplatinum injury].
abstract: OBJECTIVE
  To evaluate Amifostin's effect on protecting kidney from cisplatinum (DDP) injury and its adverse reactions and safety.
  
  
  METHODS
  193 Patients were divided into two groups randomly: 102 in group A (treatment group) and 91 in group B (control group). Indexes such as blood routine, blood calcium, liver function, blood urea nitrogen (BUN), cretinine (C), and urinary N-acetyl-beta-D-glucosaminidase (NAG)/C and micro-albumin (MAB/C) were monitored at different intervals before or after treatment.
  
  
  RESULTS
  In the two courses of treatment in both groups, the deviation (D) values of MAB/C before treatment and on D2 in group A were lower than those in grop B (P < 0.05), so were those before treatment and on D4, D6, D10 and D14 (P < 0.01). The D-values of NAG/C before treatment and on D4, D6, D10 and D14 in the first course of group A were obviously lower than those on the corresponding days in group B (P < 0.01), so were those before treatment and on D2, D4, D6, D10 and D14 in the second course (P < 0.01).
  
  
  CONCLUSIONS
  The reduction of MAB/C and NAG/C by Amifostin in group A demonstrates that: Amifostin is able to effectively protect the renal function, regardless of the type of tumor. In contrast with group B, Amifostin in group A shows no protection for tumor in lung cancer and ovarian cancer. The main side effects of Amifostin are mild hypotension, nausea, vomiting and hypocalcemia in some patients.
authors.affiliation: China and Japan Friendship Hospital, Beijing You An Hospital, Beijing 10029, China.
authors.forename: Huijuan
authors.initials: H
authors.lastname: Cui
authors.forename: Shujun
authors.initials: S
authors.lastname: Zhang
authors.forename: Peiwen
authors.initials: P
authors.lastname: Li
authors.forename: Zhongzhen
authors.initials: Z
authors.lastname: Guan
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Sun
authors.forename: Keng
authors.initials: K
authors.lastname: Shen
authors.forename: Ming
authors.initials: M
authors.lastname: Wu
authors.forename: Xiaodian
authors.initials: X
authors.lastname: Hu
authors.forename: Shujun
authors.initials: S
authors.lastname: Liu
authors.forename: Lijun
authors.initials: L
authors.lastname: Di
authors.forename: Shucai
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D004999:Amifostine / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D008875:Middle Aged; D020011:Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D020011:Protective Agents; D004999:Amifostine; D002945:Cisplatin